Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Monthly Archives: July 2015

Generic Pharmaceutical Association Names Chester ‘Chip’ Davis as President and CEO

Chip Davis

Chip Davis

Washington, DC, July 23, 2015 ― The Generic Pharmaceutical Association (GPhA) yesterday announced it had named Chester “Chip” Davis, Jr. President and CEO.  Davis, who will assume the role effective August 18, succeeds CEO Ralph Neas.

Davis currently is the Executive Vice President for Advocacy and Member Relations at PhRMA.  He leads PhRMA’s federal, state and international government relations and advocacy efforts, and is also responsible for membership recruitment and retention. Continue reading

Courier-Post Commentary: Congress’ Innovation Act Would Undermine New Jersey Research

Patent Reform capitolTrenton, NJ, July 22, 2015The Courier-Post has published a commentary authored by West Caldwell Mayor Joseph Tempesta Jr. regarding patent reform, which is currently being considered in the Congress.  Mayor Tempesta writes:

An experimental drug from New Jersey startup Actinobac Biomed could improve the lives of 40 million Americans suffering from white blood cell diseases like asthma, psoriasis, lupus and cancer.  The medicine has proven effective in animal testing and will soon enter clinical trials.

But if Congress proceeds with a new intellectual property law that discourages such trials, patients could lose access to this potentially revolutionary treatment and dozens of others like it. New Jersey’s representatives in Washington should oppose the law to ensure a healthy environment for Garden State medical research. Continue reading

NJ Spotlight: New Jersey Health Commissioner Mary O’Dowd Looks Back on Tenure

Mary O'Dowd

NJ Health Commissioner Mary O’Dowd

Trenton, NJ, July 22, 2015 ― In a NJ Spotlight story by Andrew Kitchenman, Mary E. O’Dowd looks back on the past seven years with the state Department of Health — the last four years as Commissioner.

Commissioner O’Dowd focuses on the details of policy implementation, including improving the state’s health-information technology and implementing a new federally funded program to improve healthcare delivery.

And it’s that same focus on the details that earned O’Dowd praise from observers who’ve given her high marks since she took over as commissioner at age 33 in 2011. Continue reading

Governor Christie Names Thomas P. Scrivo as New Chief Counsel

Trenton, NJ, July 22, 2015 ― Governor Chris Christie has announced changes to his senior staff leadership, including the departure of Chief Counsel Chris Porrino, following nearly four years of service in the Christie Administration, including the last 18 months as Chief Counsel.

Thomas P. Scrivo of McElroy, Deutsch, Mulvaney and Carpenter will succeed Porrino as Chief Counsel to the Governor.

Porrino, who will return to practice at his former firm in the private sector, Lowenstein Sandler LLP, will serve through the end of the month, when he will rejoin Lowenstein Sandler, as Co-Chair of the firm’s national litigation practice. Continue reading

Report: Venture Capital Investments in NJ Strong in Q2; Biotech Investments Lead

Newark, NJ, July 21, 2015 ― Melanie Anzidei reports in The Record that venture capitalists invested $184.4 million in 13 deals with New Jersey companies during the second quarter, $100 million more than the same period last year, according to a report on venture capital, as the investment climate improved in the Garden State.

The dollar amount of investments is larger than the first three periods of 2014, according to The MoneyTree Report, issued by PricewaterhouseCoopers and Washington-based National Venture Capital Association, based on data from Thomson Reuters. Continue reading

New Jersey Chamber and Baker Tilley Survey: State’s High Cost Is Impeding Economic Recovery

NJ Chamber of Commerce LogoTrenton, NJ, July 21, 2015 ― High taxes/high cost-of-living remains the single biggest obstacle to a full-blown economic recovery in New Jersey, say members of the State Chamber of Commerce in the Baker Tilly ̶ New Jersey Chamber of Commerce Spring 2015 Economic Outlook Survey.

To gauge the difficulty of luring companies to New Jersey and retaining them, the survey asked executives to identify the most significant problems New Jersey leaders should address to improve the state’s business climate and quality of life. Respondents could name as many issues as they thought necessary. Continue reading

Rowan Research Gives Hope to Patients of Canavan Disease; Through Commercial Agreement with Bamboo Therapeutics

Rowan University logoGlassboro, NJ, July 21, 2015 ― Rowan University and Bamboo Therapeutics, Inc. have entered into an asset transfer agreement to commercialize a novel gene therapy for the treatment of Canavan disease.

A rare but devastating neurological disease that tragically takes a child’s life by age 10, Canavan disease is one of the most common and complex degenerative cerebral diseases in infants. Continue reading

NIH Joins Public-Private Partnership to Fund Research on Autism Biomarkers

Bethesda, MD, July 21, 2015 ― Government, nonprofit and other private partners will fund a multi-year project to develop and improve clinical research tools for studying autism spectrum disorder (ASD).

he project will receive a total of $28 million over the next four years to test and refine clinical measures of social impairment in ASD in order to better evaluate potential behavioral and drug therapies.  It is supported by the National Institutes of Health (NIH), the Foundation for the NIH (FNIH), the Simons Foundation Autism Research Initiative (SFARI), and others.

Continue reading

Governor Christie Strengthens New Jersey’s Prescription Monitoring Program to Further Curb Prescription Drug Abuse

Trenton, NJ, July 20, 2015 ― Empowering healthcare professionals with effective tools to join the fight against prescription drug abuse, Governor Chris Christie signed legislation that expands the New Jersey Attorney General’s Division of Consumer Affairs Prescription Monitoring Program (PMP), an online database that tracks the prescription sale of drugs classified as controlled dangerous substances (CDS).

The bill, S1998, expands existing law with regard to access, registration, and utilization of the NJPMP. The new changes will help prevent “doctor shopping” that often occurs with prescription and opioid abuse.

“We have taken great strides in the fight against opiate abuse through a comprehensive strategy that encourages healthcare professionals, treatment providers, law enforcement, and members of the public to each embrace their role in addressing this healthcare crisis,” Governor Christie said. Continue reading

Alzheimer’s Researchers Gather in DC Amid Signs of Progress for Treatment

Alzheimer's RibbonWashington, DC, July 20, 2015The Washington Post’sFredrick Kunkle reports that more than 4,000 scientists from around the world will gather in Washington, DC this week to share the latest findings and ideas on Alzheimer’s disease, with some saying that the odds of finding effective treatments look promising even as an aging society increases the urgency of finding a cure.

The Alzheimer’s Association International Conference, which runs from Sunday through Thursday, is expected to highlight a number of recent trends in the field. Continue reading